The biotech space is often looked at closely to see which innovative companies could change the world with their offerings. One small cap firm may soon redefine how we fight viruses with game changing broad-spectrum antiviral nanomedicines. These drugs work safely and effectively even against variants. The company's lead drug alone addresses a $1.8 to $8 billion market! This lead drug candidate is a novel broad-spectrum antiviral that is being studied for the treatment of RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections.
The treatment was substantially superior to remdesivir in coronavirus infections and was found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir (Tamiflu®, Roche), peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche)!
The drug, developed in response to the COVID-19 pandemic, demonstrated exceptional safety in clinical trials, even at the highest dose levels, with NO adverse events reported. The unique mechanism of action involves mimicking a cell membrane, encapsulating and blocking the virus. Beyond COVID-19, the drug also displayed promising results against respiratory syncytial virus (RSV), offering a potential solution for infants and seniors where existing treatments like ribavirin may be contraindicated due to side effects.
There is no drug for the general treatment of RSV infection at present, enabling this tiny biotech firm's NV-387 offering to be a candidate for this $1.8 Billion to $8 Billion annual market size as estimated by GrowthPlus Reports! The company plans to advance the drug into a Phase II clinical trial for treatment of RSV infection in adults as part of the regulatory process required for registration of the drug for the treatment of pediatric RSV infection.
If you no longer wish to receive our emails, click the link below:
Unsubscribe
DailyMarketAlerts c/o CLM Media LLC 315 Ridgedale Avenue #556 East Hanover, New Jersey 07936 United States
No comments:
Post a Comment